General Information of Drug (ID: DM2R68E)

Drug Name
Ramipril
Synonyms
Acovil; Altace; Carasel; Cardace; Delix; Hypren; Hytren; Lostapres; Naprix; Pramace; Quark; Ramace; Ramiprilum; Triatec; Tritace; Vesdil; Zabien; Almirall Brand of Ramipril; Astra Brand of Ramipril; AstraZeneca Brand of Ramipril; Aventis Brand of Ramipril; Aventis Pharma Brand of Ramipril; Hoechst Brand of Ramipril; Monarch Brand of Ramipril; Promed Brand of Ramipril; Ramiprilum [Latin]; HOE 498; HOE498; Altace (TN); Hoe-498; Pramace (discontinued); Tritace (TN); Ramipril (USP/INN); Ramipril [USAN:INN:BAN]; Ramipro, Tritace, Altace, Prilace, Ramipril; N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid; [2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen; [2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2 S ,3 aS,6 aS)-1[(S)-N-[(S)-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure; (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name); (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid; (2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic; (2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p; (2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]
Indication
Disease Entry ICD 11 Status REF
Acute heart failure BD10-BD13 Approved [1]
Chronic heart failure BD1Z Approved [2]
Congestive heart failure BD10 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Stroke 8B20 Investigative [2]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 416.5
Logarithm of the Partition Coefficient (xlogp) 1.4
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
Elimination
1.5% of drug is excreted from urine in the unchanged form [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.686 micromolar/kg/day [6]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Cough Not Available BDKRB2 OTOA9D3W [7]
shorter time to lowering of blood pressure rs4344 ACE OTDF1964 [8]
Chemical Identifiers
Formula
C23H32N2O5
IUPAC Name
(2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
Canonical SMILES
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O
InChI
InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1
InChIKey
HDACQVRGBOVJII-JBDAPHQKSA-N
Cross-matching ID
PubChem CID
5362129
ChEBI ID
CHEBI:8774
CAS Number
87333-19-5
DrugBank ID
DB00178
TTD ID
D01STB
VARIDT ID
DR00031
INTEDE ID
DR2648
ACDINA ID
D00582
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiotensin-converting enzyme (ACE) TTL69WB ACE_HUMAN Inhibitor [9]
HUMAN angiotensin-converting enzyme (ACE) TTGFNPD ACE_HUMAN Inhibitor [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Peptide transporter 2 (SLC15A2) DT8QKNP S15A2_HUMAN Substrate [11]
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [11]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Adiponectin (ADIPOQ) OTNX23LE ADIPO_HUMAN Gene/Protein Processing [12]
Angiotensin-converting enzyme (ACE) OTDF1964 ACE_HUMAN Drug Response [8]
B2 bradykinin receptor (BDKRB2) OTOA9D3W BKRB2_HUMAN Drug Response [7]
Leptin (LEP) OT5Q7ODW LEP_HUMAN Gene/Protein Processing [13]
Liver carboxylesterase 1 (CES1) OT9L0LR8 EST1_HUMAN Biotransformations [14]
Platelet-derived growth factor subunit A (PDGFA) OTCMZ0W8 PDGFA_HUMAN Gene/Protein Processing [15]
Platelet-derived growth factor subunit B (PDGFB) OTMFMFC3 PDGFB_HUMAN Gene/Protein Processing [15]
Renin (REN) OT52GZR2 RENI_HUMAN Gene/Protein Processing [16]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute heart failure
ICD Disease Classification BD10-BD13
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Angiotensin-converting enzyme (ACE) DTT SLC33A1 2.62E-01 -0.01 -0.06
Peptide transporter 1 (SLC15A1) DTP PEPT1 6.91E-01 8.30E-03 7.24E-02
Peptide transporter 2 (SLC15A2) DTP PEPT2 8.33E-02 -3.63E-02 -1.27E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ramipril
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Spironolactone DM2AQ5N Major Increased risk of hyperkalemia by the combination of Ramipril and Spironolactone. Heart failure [BD10-BD1Z] [17]
Triamterene DM2HU9I Major Increased risk of hyperkalemia by the combination of Ramipril and Triamterene. Heart failure [BD10-BD1Z] [17]
Prazosin DMCD9YG Moderate Additive hypotensive effects by the combination of Ramipril and Prazosin. Heart failure [BD10-BD1Z] [18]
Eplerenone DMF0NQR Moderate Increased risk of hyperkalemia by the combination of Ramipril and Eplerenone. Heart failure [BD10-BD1Z] [19]
Chlorothiazide DMLHESP Moderate Additive hypotensive effects by the combination of Ramipril and Chlorothiazide. Heart failure [BD10-BD1Z] [20]
Furosemide DMMQ8ZG Moderate Additive hypotensive effects by the combination of Ramipril and Furosemide. Heart failure [BD10-BD1Z] [20]
Digoxin DMQCTIH Moderate Decreased renal excretion of Ramipril caused by Digoxin. Heart failure [BD10-BD1Z] [21]
Amiloride DMRTSGP Major Increased risk of hyperkalemia by the combination of Ramipril and Amiloride. Heart failure [BD10-BD1Z] [17]
Bumetanide DMRV7H0 Moderate Additive hypotensive effects by the combination of Ramipril and Bumetanide. Heart failure [BD10-BD1Z] [20]
Hydroflumethiazide DMVPUQI Moderate Additive hypotensive effects by the combination of Ramipril and Hydroflumethiazide. Heart failure [BD10-BD1Z] [20]
Torasemide DMXKJ6C Moderate Additive hypotensive effects by the combination of Ramipril and Torasemide. Heart failure [BD10-BD1Z] [22]
⏷ Show the Full List of 11 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Ramipril (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Ramipril and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [23]
Sodium bicarbonate DMMU6BJ Minor Decreased absorption of Ramipril due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [24]
Glimepiride DM5FSJA Moderate Increased risk of hypoglycemia by the combination of Ramipril and Glimepiride. Acute diabete complication [5A2Y] [25]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Ramipril and Repaglinide. Acute diabete complication [5A2Y] [25]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Ramipril and Glibenclamide. Acute diabete complication [5A2Y] [25]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Ramipril and Tolazamide. Acute diabete complication [5A2Y] [25]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Ramipril and Nateglinide. Acute diabete complication [5A2Y] [25]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Ramipril and Insulin-glulisine. Acute diabete complication [5A2Y] [25]
Acetohexamide DMR6N7H Moderate Increased risk of hypoglycemia by the combination of Ramipril and Acetohexamide. Acute diabete complication [5A2Y] [25]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Ramipril and Insulin-aspart. Acute diabete complication [5A2Y] [26]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Ramipril and Glipizide. Acute diabete complication [5A2Y] [25]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Ramipril and Thioguanine. Acute myeloid leukaemia [2A60] [27]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Ramipril and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [28]
Promazine DMZAL7W Moderate Additive hypotensive effects by the combination of Ramipril and Promazine. Appearance/behaviour symptom [MB23] [29]
Linezolid DMGFPU2 Moderate Additive hypotensive effects by the combination of Ramipril and Linezolid. Bacterial infection [1A00-1C4Z] [30]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Ramipril and Cariprazine. Bipolar disorder [6A60] [29]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Ramipril and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [31]
Mannitol DMSCDY9 Moderate Additive hypotensive effects by the combination of Ramipril and Mannitol. Bronchiectasis [CA24] [20]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Ramipril and Olopatadine. Conjunctiva disorder [9A60] [32]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Ramipril and Drospirenone. Contraceptive management [QA21] [33]
Ardeparin DMYRX8B Moderate Increased risk of hyperkalemia by the combination of Ramipril and Ardeparin. Coronary thrombosis [BA43] [34]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Ramipril and Isocarboxazid. Depression [6A70-6A7Z] [30]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Ramipril and OPC-34712. Depression [6A70-6A7Z] [29]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Ramipril and Phenelzine. Depression [6A70-6A7Z] [30]
Nitroglycerin DMQ2491 Moderate Additive hypotensive effects by the combination of Ramipril and Nitroglycerin. Diabetic foot ulcer [BD54] [35]
SODIUM CITRATE DMHPD2Y Minor Decreased absorption of Ramipril due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [24]
Diazepam DM08E9O Moderate Additive hypotensive effects by the combination of Ramipril and Diazepam. Epilepsy/seizure [8A61-8A6Z] [36]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Ramipril and Cannabidiol. Epileptic encephalopathy [8A62] [37]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Ramipril and Ethacrynic acid. Essential hypertension [BA00] [22]
Bendroflumethiazide DM7EVLC Moderate Additive hypotensive effects by the combination of Ramipril and Bendroflumethiazide. Essential hypertension [BA00] [20]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Ramipril and Phenoxybenzamine. Essential hypertension [BA00] [18]
Benzthiazide DMQWZ0H Moderate Additive hypotensive effects by the combination of Ramipril and Benzthiazide. Essential hypertension [BA00] [20]
Acetazolamide DM1AF5U Moderate Additive hypotensive effects by the combination of Ramipril and Acetazolamide. Glaucoma [9C61] [20]
Methazolamide DM7J2TA Moderate Additive hypotensive effects by the combination of Ramipril and Methazolamide. Glaucoma [9C61] [20]
Dichlorphenamide DMH7IDQ Moderate Additive hypotensive effects by the combination of Ramipril and Dichlorphenamide. Glaucoma [9C61] [22]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Ramipril and Procarbazine. Hodgkin lymphoma [2B30] [30]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Ramipril and Brentuximab vedotin. Hodgkin lymphoma [2B30] [38]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Ramipril and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [39]
Didanosine DMI2QPE Minor Decreased absorption of Ramipril due to altered gastric pH caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [24]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Ramipril and Isosorbide mononitrate. Hydrocephalus [8D64] [35]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Ramipril and Mipomersen. Hyper-lipoproteinaemia [5C80] [40]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Ramipril and Teriflunomide. Hyper-lipoproteinaemia [5C80] [41]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Ramipril and BMS-201038. Hyper-lipoproteinaemia [5C80] [42]
Eprosartan DM07K2I Major Increased risk of hyperkalemia by the combination of Ramipril and Eprosartan. Hypertension [BA00-BA04] [34]
Aliskiren DM1BV7W Major Increased risk of hyperkalemia by the combination of Ramipril and Aliskiren. Hypertension [BA00-BA04] [43]
Losartan DM72JXH Major Increased risk of hyperkalemia by the combination of Ramipril and Losartan. Hypertension [BA00-BA04] [34]
Doxazosin DM9PLRH Moderate Additive hypotensive effects by the combination of Ramipril and Doxazosin. Hypertension [BA00-BA04] [18]
Diltiazem DMAI7ZV Minor Additive hypotensive effects by the combination of Ramipril and Diltiazem. Hypertension [BA00-BA04] [44]
TAK-491 DMCF6SX Major Increased risk of hyperkalemia by the combination of Ramipril and TAK-491. Hypertension [BA00-BA04] [34]
Indapamide DMGN1PW Moderate Additive hypotensive effects by the combination of Ramipril and Indapamide. Hypertension [BA00-BA04] [20]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Ramipril and Trichlormethiazide. Hypertension [BA00-BA04] [20]
Telmisartan DMS3GX2 Major Increased risk of hyperkalemia by the combination of Ramipril and Telmisartan. Hypertension [BA00-BA04] [45]
Irbesartan DMTP1DC Major Increased risk of hyperkalemia by the combination of Ramipril and Irbesartan. Hypertension [BA00-BA04] [45]
Hydrochlorothiazide DMUSZHD Moderate Additive hypotensive effects by the combination of Ramipril and Hydrochlorothiazide. Hypertension [BA00-BA04] [20]
Potassium chloride DMMTAJC Major Increased risk of hyperkalemia by the combination of Ramipril and Potassium chloride. Hypo-kalaemia [5C77] [20]
Tolvaptan DMIWFRL Moderate Increased risk of hyperkalemia by the combination of Ramipril and Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [46]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Ramipril and Propiomazine. Insomnia [7A00-7A0Z] [29]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Ramipril and ITI-007. Insomnia [7A00-7A0Z] [29]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Ramipril and Methotrexate. Leukaemia [2A60-2B33] [37]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Ramipril and Porfimer Sodium. Lung cancer [2C25] [47]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Ramipril and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [48]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Ramipril and Idelalisib. Mature B-cell leukaemia [2A82] [49]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Ramipril and Clofarabine. Mature B-cell lymphoma [2A85] [50]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Ramipril due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [41]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Ramipril and Ozanimod. Multiple sclerosis [8A40] [30]
Prochlorperazine DM53SRA Moderate Additive hypotensive effects by the combination of Ramipril and Prochlorperazine. Nausea/vomiting [MD90] [29]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Ramipril and Promethazine. Nausea/vomiting [MD90] [29]
Thiethylperazine DMU3IET Moderate Additive hypotensive effects by the combination of Ramipril and Thiethylperazine. Nausea/vomiting [MD90] [29]
Chlorthalidone DM4DMBT Moderate Additive hypotensive effects by the combination of Ramipril and Chlorthalidone. Oedema [MG29] [20]
Metolazone DMB39LO Moderate Additive hypotensive effects by the combination of Ramipril and Metolazone. Oedema [MG29] [20]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Ramipril and Polythiazide. Oedema [MG29] [20]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Ramipril and Safinamide. Parkinsonism [8A00] [30]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Ramipril and Rasagiline. Parkinsonism [8A00] [30]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Ramipril and Terazosin. Prostate hyperplasia [GA90] [18]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Ramipril and Silodosin. Prostate hyperplasia [GA90] [18]
Alfuzosin DMZVMKF Moderate Additive hypotensive effects by the combination of Ramipril and Alfuzosin. Prostate hyperplasia [GA90] [18]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Ramipril and Levomepromazine. Psychotic disorder [6A20-6A25] [29]
Fluphenazine DMIT8LX Moderate Additive hypotensive effects by the combination of Ramipril and Fluphenazine. Psychotic disorder [6A20-6A25] [29]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Ramipril and Leflunomide. Rheumatoid arthritis [FA20] [41]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Ramipril and Quetiapine. Schizophrenia [6A20] [29]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Ramipril and Mesoridazine. Schizophrenia [6A20] [29]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Ramipril and Iloperidone. Schizophrenia [6A20] [29]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Ramipril and Paliperidone. Schizophrenia [6A20] [29]
Loxapine DM8AI9U Moderate Additive hypotensive effects by the combination of Ramipril and Loxapine. Schizophrenia [6A20] [29]
Haloperidol DM96SE0 Moderate Additive hypotensive effects by the combination of Ramipril and Haloperidol. Schizophrenia [6A20] [29]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Ramipril and Perphenazine. Schizophrenia [6A20] [29]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Ramipril and Molindone. Schizophrenia [6A20] [29]
Chlorpromazine DMBGZI3 Moderate Additive hypotensive effects by the combination of Ramipril and Chlorpromazine. Schizophrenia [6A20] [29]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Ramipril and Thiothixene. Schizophrenia [6A20] [29]
Clozapine DMFC71L Moderate Additive hypotensive effects by the combination of Ramipril and Clozapine. Schizophrenia [6A20] [29]
Ziprasidone DMM58JY Moderate Additive hypotensive effects by the combination of Ramipril and Ziprasidone. Schizophrenia [6A20] [29]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Ramipril and Risperidone. Schizophrenia [6A20] [29]
Olanzapine DMPFN6Y Moderate Additive hypotensive effects by the combination of Ramipril and Olanzapine. Schizophrenia [6A20] [29]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Ramipril and Amisulpride. Schizophrenia [6A20] [29]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Ramipril and Asenapine. Schizophrenia [6A20] [29]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Ramipril and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [37]
Epirubicin DMPDW6T Moderate Increased risk of hepatotoxicity by the combination of Ramipril and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [23]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Ramipril and Naltrexone. Substance abuse [6C40] [51]
Tacrolimus DMZ7XNQ Moderate Increased risk of hyperkalemia by the combination of Ramipril and Tacrolimus. Transplant rejection [NE84] [52]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Ramipril and Tolbutamide. Type 2 diabetes mellitus [5A11] [25]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Ramipril and Chlorpropamide. Type 2 diabetes mellitus [5A11] [25]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Ramipril and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [25]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Ramipril and Insulin degludec. Type-1/2 diabete [5A10-5A11] [25]
Trimethoprim DMM7CHK Major Increased risk of hyperkalemia by the combination of Ramipril and Trimethoprim. Urinary tract infection [GC08] [53]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Ramipril and Methdilazine. Vasomotor/allergic rhinitis [CA08] [29]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Ramipril and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [54]
⏷ Show the Full List of 106 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 33 E00261 19116 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Hydrazine yellow E00409 164825 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Meglumine E00181 8567 Buffering agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium oxide E00232 14792 Anticaking agent; Diluent; Emulsifying agent; Glidant; Tonicity agent
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 26 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ramipril 10 mg capsule 10 mg Oral Capsule Oral
Ramipril 2.5 mg capsule 2.5 mg Oral Capsule Oral
Ramipril 1.25 mg capsule 1.25 mg Oral Capsule Oral
Ramipril 5 mg capsule 5 mg Oral Capsule Oral
Ramipril 2.5 mg tablet 2.5 mg Oral Tablet Oral
Ramipril 1.25 mg tablet 1.25 mg Oral Tablet Oral
Ramipril 5 mg tablet 5 mg Oral Tablet Oral
Ramipril 10 mg tablet 10 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 202392.
2 Ramipril FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6339).
4 ClinicalTrials.gov (NCT04366050) Ramipril for the Treatment of COVID-19. U.S. National Institutes of Health.
5 BDDCS applied to over 900 drugs
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens. 2007 Oct;25(10):2082-92. doi: 10.1097/HJH.0b013e3282b9720e.
9 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
10 Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Curr Cardiol Rep. 2020 Apr 14;22(5):31.
11 Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
12 Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. Eur Heart J. 2007 Jun;28(12):1440-7. doi: 10.1093/eurheartj/ehm101. Epub 2007 May 5.
13 Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol. 2010 Apr 1;140(1):73-81. doi: 10.1016/j.ijcard.2008.11.017. Epub 2008 Dec 6.
14 Contribution of human esterases to the metabolism of selected drugs of abuse. Toxicol Lett. 2015 Jan 5;232(1):159-66. doi: 10.1016/j.toxlet.2014.10.026. Epub 2014 Oct 24.
15 Ramipril inhibits in vitro human mesangial cell proliferation and platelet-derived growth factor expression. Exp Nephrol. 1999 May-Jun;7(3):229-35. doi: 10.1159/000020606.
16 Effects of an angiotensin converting enzyme inhibitor, ramipril, on intracranial circulation in healthy volunteers. off. Br J Clin Pharmacol. 1992 Sep;34(3):224-30. doi: 10.1111/j.1365-2125.1992.tb04128.x.
17 Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812. [PMID: 14525902]
18 Baba T, Tomiyama T, Takebe K "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med 322 (1990): 1237. [PMID: 1970122]
19 Product Information. Inspra (eplerenone). Searle, Chicago, IL.
20 Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
21 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
22 Murphy BF, Whitworth JA, Kincaid-Smith P "Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics." Br Med J 288 (1984): 844-5. [PMID: 6322905]
23 Cerner Multum, Inc. "Australian Product Information.".
24 Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P "Impairment of captopril bioavailability by concomitant food and antacid intake." Int J Clin Pharmacol Ther Toxicol 22 (1984): 626-9. [PMID: 6389377]
25 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
26 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
27 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
28 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
29 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
30 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
31 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
32 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
33 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
34 Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
35 Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7. [PMID: 1901528]
36 Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595. [PMID: 9518913]
37 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
38 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
39 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
40 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
41 Canadian Pharmacists Association.
42 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
43 Health Canada "Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ) or aliskiren/hydrochlorothiazide (RASILEZ HCT)." .
44 DeQuattro V "Comparison of benazepril and other antihypertensive agents alone and in combination with the diuretic hydrochlorothiazide." Clin Cardiol 14 (1991): iv28-32. [PMID: 1893639]
45 Product Information. Micardis (telmisartan). Boehringer-Ingelheim, Ridgefield, CT.
46 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
47 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
48 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
49 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
50 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
51 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
52 Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
53 Canaday DH, Johnson JR "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 438. [PMID: 8304666]
54 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.